3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease

JSCAI-published data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months

Excerpt from the Press Release:

SANTA ROSA, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced publication of 36-month results from the DETOUR2 clinical trial evaluating Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR™ System in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI).

The DETOUR2 Trial is a prospective, single-arm, international, multi-center clinical evaluation of the safety and effectiveness of PTAB using the DETOUR System in patients with long and complex femoropopliteal lesions. The prospective, multicenter, international study enrolled 202 patients across 32 clinical sites and results demonstrated sustained safety and durable clinical outcomes through 36 months, supporting PTAB with the DETOUR System as a minimally invasive alternative for patients with complex peripheral arterial disease (PAD). This publication comes on the heels of additional progress with the PTAB1 study, a prospective, multi-center, real-world registry evaluating the safety and clinical performance of the DETOUR System, which has now enrolled more than 200 patients and is tracking outcomes in patients with complex, long-segment PAD.

“Long-segment femoropopliteal disease remains one of the most challenging areas in peripheral vascular intervention,” said Dr. Prakash Krishnan, MD, Icahn School of Medicine at Mount Sinai and lead author of the study.

Click the button below to read the entire Press Release:

Continue Reading The Press Release